Clinical Evidence of Antidepressant Effects of Insulin and Anti-Hyperglycemic Agents and Implications for the Pathophysiology of Depression-A Literature Review
Young Sup Woo1, Hyun Kook Lim1, Sheng-Min Wang1
1Department of Psychiatry, College of Medicine, The Catholic University of Korea, Seoul 07345, Korea.
Abstract:
Close connections between depression and type 2 diabetes (T2DM) have been suggested by many epidemiological and experimental studies. Disturbances in insulin sensitivity due to the disruption of various molecular pathways cause insulin resistance, which underpins many metabolic disorders, including diabetes, as well as depression. Several anti-hyperglycemic agents have demonstrated antidepressant properties in clinical trials, probably due to their action on brain targets based on the shared pathophysiology of depression and T2DM. In this article, we review reports of clinical trials examining the antidepressant effect of these medications, including insulin, metformin, glucagon like peptide-1 receptor agonists (GLP-1RA), and peroxisome proliferator-activated receptor (PPAR)-γ agonists, and briefly consider possible molecular mechanisms underlying the associations between amelioration of insulin resistance and improvement of depressive symptoms. In doing so, we intend to suggest an integrative perspective for understanding the pathophysiology of depression.
Insights
Many studies link depression and type 2 diabetes (T2DM). Certain anti-diabetic drugs show antidepressant effects, possibly by targeting shared molecular pathways. This review explores these connections and potential treatments.
Area of Science:
- Endocrinology
- Neuroscience
- Psychiatry
Background:
- Type 2 diabetes (T2DM) and depression share underlying molecular pathways, including insulin resistance.
- Insulin resistance disrupts molecular pathways, contributing to both metabolic disorders and depression.
- Epidemiological and experimental studies suggest a strong connection between T2DM and depression.
Purpose of the Study:
- To review clinical trials on the antidepressant effects of anti-hyperglycemic agents.
- To explore the molecular mechanisms linking insulin resistance amelioration and depressive symptom improvement.
- To propose an integrative perspective on the pathophysiology of depression.
Main Methods:
- Review of clinical trial reports on specific anti-hyperglycemic medications.
- Examination of medications including insulin, metformin, GLP-1 receptor agonists (GLP-1RA), and PPAR-γ agonists.
- Brief consideration of molecular mechanisms involved.
Main Results:
- Several anti-hyperglycemic agents have demonstrated antidepressant properties in clinical trials.
- These effects are likely mediated by actions on brain targets involved in shared pathophysiology.
- Evidence suggests a link between improved insulin sensitivity and reduced depressive symptoms.
Conclusions:
- Anti-hyperglycemic agents may offer a novel therapeutic avenue for depression.
- Understanding shared pathophysiology can lead to integrated treatment strategies.
- Further research into molecular mechanisms is warranted for developing targeted therapies.
More Related Videos
Related Concept Videos
Oral Hypoglycemic Agents: Biguanides and Glitazones
Hormones Regulating Blood Glucose
In addition to accelerating glucose uptake and utilization, insulin has...
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
Insulin and C-peptide are...
Antidepressant Drugs: MAOIs and Other Agents
Insulin: The Receptor and Signaling Pathways
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...


